Artelo Biosciences (ARTL) vs Biodexa Pharmaceuticals American Depositary Shs (BDRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Artelo Biosciences is the larger company by market cap ($1.8 million vs $1.2 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | BDRX |
|---|---|---|
| Share price | $3.37 | $0.5237 |
| Market cap | $1.85M | $1.15M |
| 1-day change | -1.17% | -7.11% |
| P/E ratio (TTM) | — | 0.01 |
| EPS (TTM) | $-136.26 | $63.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $179.19 | $52.05 |
| 52-week low | $3.33 | $0.511 |
| Distance from 52-week high | -98.12% | -98.99% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1601.36% |
| Average volume | 480.72K | 3.72M |
| Shares outstanding | 547.77K | 2.20M |
| Employees | 7 | 11 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Healthcare · Biotechnology · 7 employees
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Healthcare · Biotechnology · 11 employees
ARTL vs BDRX FAQ
Which is bigger, Artelo Biosciences or Biodexa Pharmaceuticals American Depositary Shs?
Artelo Biosciences (ARTL) is larger, with a market capitalization of $1.85M compared with $1.15M for Biodexa Pharmaceuticals American Depositary Shs (BDRX).
Are Artelo Biosciences and Biodexa Pharmaceuticals American Depositary Shs in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.